ALSO NOTED: Teva, Barr get OK to sell Fosamax copies; Ranbaxy wins FDA nod for copycat Nexium;

> Teva and Barr Pharmaceuticals both got FDA approval for their generic versions of Merck's osteoporosis drug Fosamax, which went off patent yesterday. Report

> India's Ranbaxy got the tentative FDA nod for its copycat form of AstraZeneca's Nexium heartburn pill, which is still under patent. Report

> Millennium Pharmaceuticals posted fourth-quarter profits of $41.06 million on revenues of $181.19 million. Report

> Wyeth hired Timothy Cost to be senior vice president for corporate affairs; previously, cost handled corporate affairs at ARAMARK. Report

> Swiss-based Octapharma is moving its U.S. headquarters to a 15,000-square-foot facility in Hoboken, NJ. Report

> Biogen Idec reported a big boost in quarterly profits, largely due to strong sales of its multiple sclerosis drugs and a cancer med it markets jointly with Genentech. Report

> French authorities are investigating GlaxoSmithKline and Sanofi Pasteur over an anti-hepatitis B vaccination campaign in the 1990s. At issue is whether the companies fully disclosed the shot's potential side effects. Report

> A new blend of a genetically modified chimp adenovirus and a malaria gene is proving promising as a potential vaccine against malaria. Report

> Speculation over the prospective acquisition of CeNeS continued to mount as the company's shares shot up 70 percent yesterday. Report

> AstraZeneca is shaking up its global R&D efforts, planning to slash some 300 research positions at a major complex in the U.K. Report

> The most efficient drug development programs will rely on contributions from a variety of companies, with partnerships and outsourcing providing unique expertise to advance new therapies, according to a new study from Tufts Center for the Study of Drug Development. Report

And Finally... Prescription mac-and-cheese? Kraft Foods is working on products that will contain plant oils to kill intestinal parasites such as tapeworms. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.